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Introduction: Oesophageal atresia refers to an anomaly in foetal development in which the 
oesophagus terminates in a blind end. Whilst surgical correction is achievable in most 
patients, when a long gap is present it still represents a major challenge associated with 
higher morbidity and mortality. In this context, tissue engineering could represent a 
successful alternative to restore oesophageal function and structure. Naturally derived 
biomaterials made of decellularised tissues retain native extracellular matrix architecture and 
composition, providing a suitable bed for the anchorage and growth of relevant cell types. 
Areas covered: This review outlines the various strategies and challenges in oesophageal 
tissue engineering, highlighting the evolution of ideas in the development of decellularised 
scaffolds for clinical use. It explores the interplay between clinical needs, ethical dilemmas, 
and manufacturing challenges in the development of a tissue engineered decellularised 
scaffold for oesophageal atresia.  
Expert opinion: Current progress on oesophageal tissue engineering has enabled effective 
repair of patch defects, whilst the development of a full circumferential construct remains a 
challenge. Despite the different approaches available and the improvements achieved, a gold 
standard for fully functional tissue engineered oesophageal constructs has not been defined 
yet. 
 
1. Introduction:   
Oesophageal atresia (OA) is a congenital anomaly that affects 1:2500-5000 newborns [1]. In 
children born with the condition the continuity of the oesophagus is interrupted by a blind 
end. This prevents swallowed material from entering the stomach and requires surgery to 
create a clear passage for food. Atresia presents most commonly with distal tracheo-
oesophageal fistula (TOF), where the proximal oesophagus ends blindly at the level of about 
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the third or fourth thoracic vertebra while the distal oesophagus, enters the posterior wall of 
the trachea [1].  
From a structural point of view, OA can be classified based on the presence and position of 
the tracheo-oesophageal fistula (TOF) according to Gross classification [2]: 
• type A: isolated oesophageal atresia (8-9% of OA cases) 
• type B proximal fistula with distal atresia (1%) 
• type C: proximal atresia with distal fistula (85%) 
• type D: double fistula with intervening atresia (1-2%) 
• type E: isolated fistula (4-6%) 
When a distal TOF is not present (type A and B) there is usually a long gap between the 2 
ends of the oesophagus and reconstruction is particularly challenging.  
An antenatal ultrasound scan after 18 gestation weeks can detect signs of possible OA, 
particularly when there is no distal fistula and the baby is unable to swallow amniotic fluid, 
therefore making the stomach not visible. A definitive diagnosis however is usually made 
once the infant is born (Fig.1). Due to the impossibility of feeding the baby and the high risk 
of respiratory complications and failure, surgical intervention in the first days of life is 
required to stabilise the patient and repair the anomaly [3]. From the first reported successes 
in operative procedures in the 1940s, rates have been rising steadily due to improvements in 
surgical techniques [1] and neonatal units today often report overall operative success rate 
exceeding 95% [4]. However, these patients face post-operative complications that lead to a 
lower quality of life. These comprise of anastomotic leakage or strictures, gastro-oesophageal 
reflux and oesophageal dysmotility (Tab.1), all of which lead to recurrent hospitalisation and 
multiple surgical treatments.  
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Patients with long gap oesophageal atresia (LGOA) however, suffer the highest complication 
rates. Since oesophageal continuity cannot be achieved in a single surgery, a multi-step 
approach is required. A common strategy is for the patient to undergo surgery for 
gastrostomy formation in the first days of life. This will allow the baby to be fed while 
waiting for the oesophagus to naturally grow until a tension free anastomosis is technically 
feasible. Throughout this waiting period, which could last weeks or months, patients cannot 
however be discharged home. They are bound to an intensive care unit in view of the high 
risk of respiratory complications related to the abundant secretions that need to be constantly 
removed from the upper pouch with the use of a suctioning tube. When, insufficient 
spontaneous growth is experienced or anticipated, a different approach is adopted which 
involves lengthening procedures performed to directly and progressively reduce the gap 
between the two oesophageal pouches, allowing a subsequent tension-free anastomosis. 
There are instances, finally, where the only feasible option is oesophageal replacement. In 
these settings, a gastric transposition, colonic interposition or jejunal interposition represent 
the best available options [5]. Among them the gastric route involves transposing the whole 
stomach into the thoracic region and is preferred for the excellent blood supply of the 
stomach. Nevertheless, several complications can occur including: anastomotic leaks, 
strictures, reflux, dumping, poor gastric emptying and Barrett’s esophagitis [6]. 
In this context, developing a tissue engineered oesophageal replacement to repair a long gap 
defect would lead to better long term clinical outcomes [7]. Synthetic materials used in other 
surgical settings include polyglycolic acid (Vicryl®) and crystalline polypropylene and high-
density polyethylene (Marlex®). They can provide mechanical support, but fail to fully 
mimic the specific host tissue function and would not follow the growth of the oesophagus 
during childhood. More recent approaches have used hybrid scaffolds containing cells or 
extracellular matrix (ECM), as well as decellularised tissues. These tissues are naturally 
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derived and can better mimic the complexity of native ECM architecture [8]. This review 
aims to describe the development of tissue engineered oesophageal constructs for LGOA 
with a focus on decellularised tissue. It expounds on the clinical relevance of these studies, 
and on the hurdles to be overcome in developing such construct for clinical use.  
 
2. Discussion 
2.1 Anatomy of the oesophagus  
The oesophagus is a muscular tube that connects the pharynx to the stomach, enabling the 
passage of food and liquids. In humans, the muscle layers in the upper (cervical) part of the 
oesophagus are predominantly made of skeletal muscle, while the lower (thoracic) portion 
consists predominantly of smooth muscle cells [9]. These muscle strata represent the external 
layer of the oesophagus. Proceeding towards the lumen there is a second layer formed by 
submucosa that contains the main blood vessels, the submucosal (Meissner) nerve plexus, 
and oesophageal glands. Finally, the mucosa forms the innermost layer and is characterised 
by a nonkeratinizing stratified epithelium that changes from squamous cell epithelium 
(continuous with that of the pharynx) to columnar cell epithelium (at the gastroesophageal 
junction). The oesophagus shows increasing stiffness with pressure. While small intraluminal 
pressures are held by the muscle alone, mucosal contribution to strength increases after the 
outer diameter of the oesophagus doubles [10].  
 
2.2 Approaches to Oesophageal Regeneration  
Early approaches to tissue engineering of the oesophagus employed synthetic materials rolled 
into a tubular configuration [11,12,13]. Although they provided mechanical support, these 
constructs were not designed to interact with the in vivo environment to promote 
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regeneration. Most recent approaches combine synthetic materials with biological 
components to make a hybrid scaffold [14,15,16]. Materials of biological origin have been 
recognised as capable of better replicating the composition, microstructure, and properties of 
native tissue [8]. It is inevitable that the discussion on regenerative approaches for the 
oesophagus draws on the wealth of research involving naturally derived constructs such as 
decellularised tissues (Fig.2). 
2.2.1 Synthetics and Hybrid Scaffolds 
For over 165 years, various techniques have been tested as oesophageal replacements in 
oesophageal cancer including decalcified ivory tubes and rubber tubes [17]. In more recent 
history, surgical polymers such as Dacron® and Marlex® have been used alone or in 
combination with silicone to produce synthetic grafts [12,13,14]. In 1983, Fukushima et al. 
reported the use of a silicone tube surrounded by a Dacron mesh [14]. The survival rate after 
implantation into canine models was 44% at 1 year and 25% at 6 years. They observed the 
regeneration of the submucosa and mucosa in contact with the anastomoses, but there were 
no glands or muscle tissue, and the central part of the tube consisted of fibrotic tissue. In 
2010, Liang [18] used a nitinol-silicon composite artificial oesophagus in pigs. The rate of 
stenosis was 60%, and regeneration of a stratified epithelium was only found near the 
anastomosis. These studies provide strong evidence that although they offer mechanical 
support, synthetic materials alone are unable to promote tissue regeneration.  
Nakase in 2008 developed a scaffold consisting of absorbable polyglycolic acid associated 
with a sheet of amniotic membrane to which smooth muscle tissue was added [19]. 
Resorbable scaffolds in one group were further seeded with keratinocytes and fibroblasts. 
After implantation in dogs, stenosis was observed less than a week after implantation in the 
scaffolds without seeded cells. This complication did not occur in the cell seeded group. 
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Beckstead in 2005 developed scaffolds composed of polylactic acid, poly(lactic-co-glycolic 
acid) or polycaprolactone with different porosities and studied the effects on cell adhesion 
and proliferation [20]. Studies exploring the balance between the rate of material degradation 
and tissue remodelling are crucial because rapid scaffold degradation can lead to the collapse 
of mechanical support, while too slow degradation may impede tissue remodelling 
[21,22,23]. Recently, biological components such as cells, proteins, or specific peptide motifs 
were included in tissue engineered constructs, leading to better outcomes. Kitajima worked 
on a cell-seeded poly-glycolic acid mesh containing collagen [24] while Zhu used a series of 
Poly-DL-lactide polymers in conjunction with ECM proteins to promote oesophageal tissue 
regeneration [25,26]. Other biological material such as Alloderm® (decellularised dermis) or 
amniotic membrane have also been used [20]. More recent studies explored the effect of 
seeding appropriate cell types onto scaffolds. Saxena [27,28] experimented seeding 
oesophageal epithelial cells onto collagen scaffolds as part of a composite scaffold-
hetrocellular oesophagus, showing that seeding of a specific epithelial population leads to 
more viable scaffolds, while Nakase [19] described how seeding of a resorbable scaffold with 
keratinocytes and fibroblasts reduced complications of post implantation stenosis. 3D 
topography of scaffolds can also provide cues for regeneration. Hou in 2016 developed 
polyester-urethane scaffolds coated with vascular endothelial growth factor. The group 
showed that 3D patterned micro-grooves aligned in the direction of muscle fibres promoted 
muscle tissue regeneration [29].   
2.2.2 Decellularised Scaffolds  
2.2.2.1 Overview 
Despite growing knowledge of synthetics constructs, naturally derived scaffolds such as 
decellularised tissue can better mimic the complexity of native ECM architecture [8] and 
have been successfully used to regenerate children airway tissue [30]. Naturally derived 
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scaffolds may better mimic the physical microenvironment; providing more physiological 
substrate rigidity which impacts on stem cell fate and endogenous repair [31,32]. In addition 
to structural support, ECM exerts pleiotropic effects on cells, enabling cell anchorage, 
growth, and signalling to occur [33,34,35]. Hence, the retention of native ECM architecture is 
a priority in the decellularisation process. Table 2 provides an overview on decellularisation 
agents, in vivo procedures and post-operative outcomes from each oesophageal engineering 
study.  
Most studies involving decellularised tissue use scaffolds from the gastro-intestinal (GI) tract 
such as Surgisis®, which is an off-the-shelf product made from small intestinal submucosa 
(SIS). Its use in oesophageal tissue engineering has been studied in animal models (canine, 
porcine, rat) as well as in two clinical cases (Tab.2).  
The majority of the published studies were conducted in the cervical region. Considering the 
differences in muscle types and nervous control, engineering and surgical implantation of a 
cervical tissue oesophageal segment may differ substantially from that of a thoracic segment. 
In the next future it will be important to address the dearth of studies on the replacement of 
the thoracic oesophagus, which may be more clinically relevant in LGOA. 
2.2.2.2 Strategies in repairing full circumferential defects  
Within the studies described in Table 2, there is a clear separation of outcomes between 
repair of patch defects and circumferential defects. Studies involving patch defects were most 
likely to lead to restored oesophageal function, while circumferential replacements often led 
to stricture formation. The difference in outcomes was striking in one study involving both 
patch and circumferential defects [36]: 11 dogs with patch grafts showed no clinical signs of 
oesophageal dysfunction. In contrast, all 4 dogs with complete circumferential segmental 
graft had clinical signs of stricture. A review proposed that to achieve successful application 
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the presence of intraluminal pressure is required– grafts used in vascular applications have 
had better outcomes than those in the oesophagus, intestine, and ureter [36]. It was postulated 
that since ECMs are collapsible in their native state, remodelling events occur in collapsed 
tubes when there is no intraluminal pressure, ultimately producing non-functional structures. 
This might indicate the necessity for stenting or the use of a hybrid scaffold consisting of 
decellularised tissue and a harder synthetic material that can provide structural support. In a 
study of allogeneic aorta using a Polyflex® stent in porcine, Gaujoux reported that a stent 
was required for at least 6 months to avoid stenosis in the graft area. Using a temporary stent 
to provide structure and patency to the implanted scaffold may be necessary during the initial 
inflammatory response and tissue remodeling process before a patent oesophageal segment is 
achieved [37]. The effect of a temporary stent has been evaluated in a study on oesophageal 
reconstruction in piglets. A 5 cm long circumferential gap was repaired using a recellularised 
scaffold of SIS, with or without the presence of an endoprothesis to temporary support the 
construct. The use of the scaffold alone was associated with a high mortality rate due to rapid 
development of oesophageal stenosis, while the interposition of the endoprothesis allowed 
nutritional autonomy and tissue remodeling toward an esophageal phenotype [38].  
The introduction of exogenous cross-links to collagen molecules is a recognized method to 
stabilize collagen biomaterials and reduce antigenicity, while preserving mechanical 
properties and natural compliance. Different cross-linking techniques have been applied to 
oesophageal constructs with variable results, including the use of glutaraldehyde and genipin, 
showing the superiority of the latter in supporting epithelial adhesion and proliferation [39].  
Since 2000, Badylak and colleagues have published work on a urinary bladder matrix 
(UBM)-ECM scaffold which promotes oesophageal reconstruction. In their first study, dogs 
underwent circumferential endomucosal resection, followed by replacement with an UBM-
ECM scaffold leading to tissue regeneration and restored oesophageal function without 
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stricture formation in any of the dogs [36]. They later showed that, while ECM dependent 
cellular responses were observed in vitro, there was an indistinguishable constructive 
outcome between the use of implanted UBM and oesophageal ECM measured 14 days post 
surgery [40]. The success of these studies may be due to the intact muscularis externa since 
musculature and both parasympathetic (vagal nerve) and intrinsic innervation systems 
(submucosal and myenteric plexus), which are crucial to the maintenance of peristalsis, 
would have been left intact. This may be the common denominator in the relatively 
successful in vivo studies involving patch defects where only a small segment of the 
oesophagus is removed. This corroborates with evidence suggesting an extensive crossover 
of innervation within the oesophageal wall [41]. The presence of native tissue surrounding 
the injury may also be crucial in providing cues for regeneration. The same cannot be said for 
a circumferential resection of the entire oesophagus as this would lead to the discontinuity of 
nerve and muscular connections. In patients with atresia however, intrinsic innervation of the 
oesophagus is often already abnormal. Hence, although normal peristaltic activity throughout 
the oesophagus is the ideal outcome to work towards, the development of a circumferential 
oesophageal construct that remains patent post implantation may be a more realistic clinical 
outcome. 
2.2.2.3 Decellularisation Methods  
The different methods of decellularisation must all balance the trade-offs between complete 
cell removal to minimise antigenicity, and preservation of structural and biological 
characteristics of the matrix. Decellularising methods are based on the combined effect of 
different agents [42], which can include: 
1) Water: the first step in decellularisation often entails flushing with deionised water for a 
period of 24 to 72 hours [43,44,45]. Water flows into cells changing their osmotic pressure, 
causing them to lyse. In subsequent steps, other agents are used to remove cellular debris.  
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2) Chemical agents: detergent such as Triton X-100 or Sodium Deoxycholate (SDC) are then 
often used to solubilise cell membranes and dissociate DNA from proteins [46,47,48,49]. A 
comparison between detergents by Ozeki provided evidence that SDC was a better 
decellularising agent compared to Triton X-100 [50]. The study found that oesophagi treated 
with Triton X-100 had a more enlarged appearance after decellularisation and were more 
fragile, while the use of SDC better maintained the mucosa and submucosal layers. 
Moreover, the DNA content of SDC-treated oesophagi was significantly less than that of 
those treated with Triton X-100. Hence SDC was better for both the preservation of ECM 
characteristics and DNA removal from the matrix.  
2) Enzymatic agents: enzyme such as DNase, are often part of a decellularising protocol, to 
lyse the genetic material. 
3) Physical agents: pressure and temperature are often combined with the above agents to 
optimise the decellularisation process. 
The way the different agents have been combined and applied in specific organs and tissues 
has given rise to an array of decellularisation protocols. In 1975, Meezan [51] developed a 
protocol for isolating basement membranes from a variety of tissues, including bovine retinal 
and brain blood vessels. Conconi [52] later modified the protocol to include cycled repeats, 
producing a decellularised donor trachea that was transplanted into a patient. This method 
was then applied by Totonelli et al. in the decellularisation of rat small bowel and porcine 
oesophagus, introducing a perfusion-based approach [8,53]. The preservation of the 
oesophageal architecture was also demonstrated at x-ray phase contrast computed 
tomography (PC-CT) [54]. 
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2.2.2.4 Removal of Antigenic Materials 
Removal of nucleic acids and cell surface antigens such as the major histocompatibility 
complex are intuitively important in preventing rejection. Cells, however, are deeply 
anchored to their surrounding ECM and removal of all cell fragments is unlikely even with 
the most rigorous processing method. Additionally, the body has inherent cellular 
mechanisms, which facilitate the breakdown of DNA into nucleotides for future use [55,56]. 
Remnant DNA in decellularised-implanted matrices should be subject to the same 
degradation processes in vivo [57,58,59] as part of the remodeling process. Even 
commercially available biological scaffolds for clinical use contain trace amounts of DNA 
[60,61,62] and since the lengths of these fragments can also influence host response to the 
scafffold [60,63], some minimal criteria have been proposed to satisfy the intent of 
decellularisation [42]. 
Upon implantation, rejection may occur wh n there is recognition of cell membrane antigens 
by the immune system [58,64,65,66]. Particularly, the presence of the pig galactose-α1,3-
galactose (Gal) in xenografts has been implicated in the rejection of bioprosthetic heart 
valves, triggering a cascade that may lead to graft calcification and failure of the prosthesis 
[67]. This epitope is found in high density on the cell surface in most species but is absent in 
humans. The body produces large quantities of anti-Gal antibodies as a result of constant 
exposure to intestinal bacteria carrying the epitope. Although the decellularisation process 
removes most cells, cellular remnants containing the Gal epitope may still be present on the 
scaffold. Various strategies have been proposed to overcome this. The treatment of xenogenic 
tissue with α-galactosidase has been proposed in non-decellularised porcine grafts for repair 
of cartilage and the human anterior cruciate ligament of the knee [68]. The production of Gal-
deficient pigs for the purpose of xenotransplantation has also been successful, showing that 
the threat of antigenic epitopes can be mitigated [69].  
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For every decellularisation process, trace amounts of host DNA or antigenic material will be 
present, and the burden of proof is on those developing the process to provide evidence that 
they do not contribute negatively to remodelling. Generally, ECM scaffolds have been shown 
to be degraded rapidly by host cells post-implantation [70,71], followed by the formation of 
site-specific functional host tissue. This process is influenced by several different factors 
including the tissue source, the decellularisation protocol applied and the site of implantation. 
Hence, process-specific animal implantation studies are necessary to investigate antigenicity 
of the scaffold and tissue remodelling processes [72]. Preliminary data obtained by 
implantation of decellularised xenogeneic scaffolds demonstrated that they induce anti-
inflammatory and immunosuppressive effects, characterized by a macrophage response toward 
an M2 phenotype and an activation of the host responses away from a classical pro-
inflammatory TH1 profile [73]. 
2.2.2.5 Cell Repopulation of Decellularised Scaffolds  
A decellularised construct with a well-preserved ECM provides physiological cues for cells 
to attach and remodel the matrix. Several attempts of scaffold repopulation have been 
described with the use of different protocols for cell seeding, including the ones proposed by 
Tan [74], Marzaro [47], Wei [75] and Sjöqvist [49] (to note, there is at present an expression 
of concern about this article from the Nature Communication editorial board). Alternatively, 
direct implantation of the acellular construct has been proposed, allowing cell recruitment to 
take place in vivo.  
Appropriate cell types have been chosen targeting regeneration of either epithelial or muscle 
layers. Ohki [76] engineered oral epithelial cells in sheets and endoscopically placed over a 
mucosal resection to investigate their potential to eliminate stricture formation after 
endoscopic mucosal resection. The sheets adhered to underlying muscle tissue at the site of 
resection, providing an intact stratified epithelium and there was no evidence of stricture 
Page 13 of 41
URL: http://mc.manuscriptcentral.com/eobt  Email: David.Grech@informa.com
Expert Opinion On Biological Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Page 14 of 33 
formation. Wei [75] undertook a study to evaluate the combination of autologous oral 
mucosal epithelial cells and SIS for oesophageal repair in a canine model. The cell-seeded 
scaffolds showed faster recovery as demonstrated by barium oesophagram and body weight 
gain, and also promoted re-epithelialisation and skeletal muscle regeneration. In order to 
identify the best protocol for epithelial cells isolation and culture, Maghsoudlou and 
colleagues [77] have compared three commonly used techniques, including 1) mincing of the 
mucosa followed by trypsin incubation, 2) trypsin incubation of intact mucosa, 3) mucosa 
culture on collagen coated wells. They demonstrate that epithelial cells can be successfully 
isolated from fresh mouse oesophagi using two consecutive trypsin incubations of intact 
mucosal sheets.  
In an attempt to repopulate the muscolar layers of oesophageal scaffolds, Marzaro seeded 
autologous smooth muscle cells on a decellularised oesophageal segment to repair a circular 
defect in the thoracic oesophagus of neonate pigs [47]. Patches composing only of acellular 
matrices showed a more pronounced pro-inflammatory response with granulocyte and 
macrophage infiltration and were negative for smooth muscle actin. Whereas cell-seeded 
implants presented in-growth of smooth muscle cells, showing an organisation into small 
fascicules. Bone marrow derived mesenchymal stem cells (BMMSC) have also been thought 
to promote regeneration of the muscle. Tan showed that the grafting of BMMSC to SIS in a 
patch defect model in canine cervical oesophagus promoted re-epithelialisation with almost 
no pro-inflammatory reaction [74]. At 12 weeks post-surgery, long bundles of skeletal 
muscles and greater micro vessel density were observed. The study also showed that 
implanted BMMSC engrafted and differentiated into myocyte-like cells at the implant site.   
In the context of scaffold repopulation, future possible options could include the use of a 
modular approach and seeding cells of autologous source. A modular approach would aim to 
recognize the biological and mechanical function of the different tissue layers in the 
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oesophagus. This could involve the repopulation of individual tissue layers, combined 
together in a later step, or the simultaneous seeding of multiple cell types onto the same 
scaffold. The use of site-specific cues provided by the ECM could favour this modular 
approach, as seen in the regeneration of rat forearms using decellularised scaffolds re-
populated with cell types of appropriate phenotype [78]. Moreover, whilst the use of 
autologous colonic and gastric interpositions is associated with long-term complications 
[5,6,79,80], the use of autologous cells for recellularisation of a scaffold should not be 
excluded – more so if the cells can be retrieved through non-invasive methods that leave no 
permanent damage. Recellularising a scaffold surface with autologous cells would allow self-
recognition of the construct by the patient's immune system, avoiding a rejection response 
towards the cell component. 
2.2.3 Scaffolds source and Ethics 
Before development of a therapeutic, careful consideration is needed for the choice of tissue 
for the scaffold, its ease of obtainability, and ethical implications that may arise. The sections 
below outline 2 main possible tissue sources. 
2.2.3.1 Allogeneic scaffold source  
Since the pioneering work of Alexis Carrel, surgical transplantation of human organs from 
deceased and living donors to patients has become a worldwide practice, saving the lives of 
many [81,82]. Currently, the oesophagus is not an organ that is harvested for transplantation, 
and could be a potential tissue source. There are two difficulties to this in context of neonatal 
oesophageal atresia. Firstly, there is little precedent from obtaining tissues from neonates. 
Organ donation can only proceed if consent is available under the Human Tissue Act 2004 
[81]. In neonates, there can be no consent given by the donor, hence clinicians need to 
consider that asking for consent and undertaking any medical procedures on the infant may 
be a source of distress for the family. There may also be procedural complications since it is 
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difficult to confidently diagnose brain-stem death in infants from 37 weeks gestation to two 
months [83]. The field of neonatal organs transplantation is rapidly evolving due to the 
constant demand of organs as well as to the development of specific guidelines, including the 
ones recently produced by a task force of experts in the UK and endorsed by the local Royal 
College of Paediatrics [84]. So far only a few cases of neonatal organ donation have been 
described, a first but significant step to address issues arising from this area of transplant 
medicine. In this context, we cannot exclude that in the next future oesophagi of allogeneic 
source could be harvested from neonatal donors and decellularised to produce scaffold for 
LGOA repair.  
The development of advanced therapeutic medical products (ATMPs) is likely to follow a 
mixed funding route with some private sector investment. Private investment in the 
development of an ATMP would require financial remuneration, but many individuals may 
be averse to a process where organs donated through philanthropy are used to generate a 
product that can be sold for profit. These issues should be explored through wider public 
discourse since such a model will have social and political ramifications.  
2.2.3.2 Xenogenic scaffold source 
One way to circumvent the issues faced by allogeneic donor material is the use of 
oesophageal matrices of xenogenic origin, readily available on demand and prepared in a way 
that reduces variability of the scaffold.  
In addition to being readily available, there is also precedence for the use of porcine tissue in 
humans. Porcine patellar tendons have been shown to successfully replace human anterior 
cruciate ligaments in cases of injury [85], while glutaraldehyde fixed porcine aortic valves 
have been used as a bioprosthetic heart valve replacement since the 1960s. The latter has 
improved clinical outcomes by reducing the need for lifelong anticoagulation required in 
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mechanical valves, but studies have also highlighted risks when xenogenic antigens were not 
fully removed [65,67,86,87]. 
 
3. Conclusion 
This review has described the clinical need for a tissue engineered oesophageal construct in 
neonatal long gap oesophageal atresia.  The evolution of ideas in the field can be tracked – 
from the use of synthetic materials for mechanical support in initial studies to the 
introduction of biological components such as ECM proteins and cells as part of the 
construct. In the field of oesophageal tissue engineering, current progress has enabled full 
repair of patch defects due to the retention of innervation and the presence of autologous 
tissue, which provides cues for regeneration. Challenges to the development of a full 
circumferential construct remain, including the lack of normal innervation and post 
implantation stricture formation. 
This review has also explored the specific challenges in decellularised matrices for LGOA 
repair in the neonatal population. These include: 1) antenatal diagnosis, planned birth in a 
paediatric center that offers antenatal parental counseling, neonatal intensive care and 
neonatal surgery; 2) development of a full circumferential tubular construct, ideally prepared 
in advanced and stored as an off-the shelf product to be immediately available after birth to 
avoid intermediate surgery (gastrostomy) and prolonged mechanical ventilation; 3) avoidance 
of life-long immunosuppression that would negatively affect the growth and development of 
the child, preferring therefore repopulation techniques that involve cells of autologous 
source; 4) use of a scaffold that "grows" with the patient to avoid recurrent surgical 
interventions to substitute/upsize the construct itself; 4) future possible use of decellularised 
Page 17 of 41
URL: http://mc.manuscriptcentral.com/eobt  Email: David.Grech@informa.com
Expert Opinion On Biological Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Page 18 of 33 
oesophagi from allogeneic sources, in view of the new guidelines on neonatal organs 
transplantation.  
 As a limitation it is important to note that, although animal studies are a necessary pre-
clinical step, they may not closely reflect the specific clinical problem. We recognise that the 
research cited might not be specifically focused on the paediatric population, and knowledge 
had to be inferred from the valuable studies conducted on adult oesophageal reconstruction. 
Lastly, in vivo studies on tissue engineered oesophagus concentrated mostly on the cervical 
oesophagus. This may be less relevant since most clinical needs in LGOA are in the thoracic 
oesophagus, which has different musculature and innervation.  
As the field continues to develop, the gold standard for fully functional tissue engineered 
constructs in LGOA has not been defined yet, leaving the medical field in need of a definitive 
solution for those suffering from the disease.   
 
4. Expert Opinion 
Long gap oesophageal atresia (LGOA) continues to represent a major challenge in paediatric 
surgery. Available options involve multiple stage procedures and are associated with low 
success rate and high risk of long-term complications.  
In this context, a tissue engineering approach could be a better option. The possibility 
envisioned is to pre-build a tubular oesophagus substitute, transplant it in the recipient and 
allow it to grow with the patient for a life-long result. The initial studies involving 
silicon/collagen stents or absorbable constructs were associated with high rate of oesophageal 
leakage or stenosis. Even when successful, they only provided a regain of organ continuity 
while lacking in the ability to restore function. Decellularised matrices have therefore been 
suggested as a better tool. These can be derived from oesophagi, harvested and processed to 
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remove the cell content while preserving the 3D structure of the extra cellular matrix (ECM). 
The latter works as a scaffold that supplies the structure and retains appropriate structural and 
biochemical signalling to guide cell repopulation.  
While different decellularisation protocols have been described and successfully applied, 
more work needs to be done to overcome the following two main challenges: developing a 
multi-strata tubular structure and achieving appropriate repopulation of the construct itself 
prior to its transplant. While superficial patch repairs of the oesophageal mucosa may be 
achievable [71, 94, 96], the successful rate falls when moving toward longer full-thickness 
tubular repairs, reaching some results only when the recipient muscularis externa is preserved 
[93]. Moreover the tubular matrices so far attempted have been mainly designed to repair 
cervical defects, while LGOA affects the intra-thoracic part of the oesophagus. This is 
possibly due to the ease of access during surgery and follow-up in the animal models 
described and to a major focus on other clinical causes of oesophageal replacement that 
involve the cervical portion of the organ. In our opinion, while smart polymers capable of 
recruiting cells in vivo could be developed in the future as off-the-shelf products, good 
functional outcome still requires appropriate recellularisation of the scaffold prior to 
transplantation. This should be ideally achieved using cells derived from the recipient to 
generate a non-antigenic construct, avoiding the need of a long-term immunosuppressive 
treatment. Cellular seeding is particularly relevant when engineering of a long segment of 
oesophagus is required. In order to have functional peristalsis, such oesophagus would in fact 
required functional integration and differentiation of neurocrest cells. 
Revascularisation of the whole construct is an additional challenge. The timeframe required 
for spontaneous vascular growth of the recipient network into the construct is inadequate in 
ensuring scaffold survival in vivo. A suggested option includes wrapping the scaffold in 
muscle or omentum prior to the thoracic transplantation [8]. This approach would not be free 
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from the complication of a second surgery and vascular reconnection. Additionally, to 
facilitate revascularisation in vivo, the use of appropriate angiogenesis stimuli and factors has 
been suggested, including studies on matrices enriched with growth factors. Type, amount 
and delivery profile of these factors should be carefully identified in order to optimise 
revascularisation. Initial release of vascular endothelial growth factor (VEGF) and basic 
fibroblast growth factor (bFGF) could be necessary to promote the formation of new vessels, 
followed by their maturation guided by factors like transforming growth factor b (TGF-b), 
platelet-derived growth factor (PDGF), and angiopoietin-1 (Ang1). An intriguing suggested 
option is therefore to enrich the scaffolds with biodegradable micro-carriers loaded with 
factors and able to release them in a timely controlled fashion.   
Alternatively, engineering of a vascularised oesophagus with its vascular supply could be 
envisaged, similarly to the jejunal transplant with vascular anastomosis. However, this is 
particularly difficult due to the complex vascular supply of the oesophagus and its difficult 
preservation after decellularization.  
Lastly but not less importantly, researchers will n ed to translate the results achieved in 
animal models into a feasible and successful application in humans. This will require a 
further joint effort between basic research and medicine in order to create an off-the shelf 
product that could be developed, stored and delivered to a surgical facility to answer a patient 
need. 
In conclusion, it has become clear how a simple decellularised matrix may not provide an 
efficient treatment in LGOA, unless it is further engineered and modified as to develop a 
more complex "smart-matrix". This could be the result of different single layer scaffolds, 
combined together and enriched with proangiogenic factors, possibly associated with tailor 
made polymers to maintain desired structure and guarantee layers interaction, and with 
absorbable engineered stents to avoid early stage stenosis. 
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The numerous efforts and attempts described in literature have not yet identified an optimal 
approach in the use of decellularised matrices in LGOA. Nevertheless, the presence of 
promising results obtained with the use of these matrices in other organs and the growing 
knowledge in the field of TE represent a constant drive towards the development of a 
functional repair option in LGOA. 
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Article highlights box: 
• Oesophageal atresia is a congenital anomaly in which the continuity of the 
oesophagus is interrupted and a fistula often connects the oesophagus to the trachea.   
• Whilst less severe cases can be successfully corrected through surgery, long gap 
atresia (LGOA) is often associated with low successful rate and high risk of long-term 
complications. Optimal treatment has not been established. 
• Tissue engineering could represent a better treatment option for patients with LGOA. 
Synthetic and hybrid scaffolds have been attempted, with variable suboptimal results.  
• Decellularised oesophageal scaffolds are now considered a better option because: 1) 
preservation of oesophageal extracellular matrix mimics the 3D structure of the native 
organ and stimulates cell repopulation in vivo; 2) removal of cell content reduces the 
risk of rejection and prevents the need of life long immunosuppression and 3) natural 
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constructs can "grow" with the patient through childhood, avoiding the need of 
multiple surgical interventions. 
• Challenges in decellularised oesophageal scaffolds production include the need to 
identify the best tissue source and optimal decellularisation protocol, develop and 
maintain a tubular patent structure, repopulate the scaffolds in its different layers, 
stimulate revascularisation, promote structural and functional integration with the 
host. 
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Figure 1. X-Ray findings and schematic representation of oesophageal atresia in newborns. Notice on X-Ray 
the feeding tube inserted and coiling in the upper oesophageal pouch suggesting Oesophageal Atresia. A: in 
the most common form the Tracheo-Oesophageal Fistula connects the trachea to the distal oesophagus 
(Type C of Gross classification) allowing the stomach to be filled with air (gastric bubble visible on X-Ray). 
B: when the fistula is not present or is connected to the upper oesophagus (Type A and B of Gross 
classification) no gastric bubble can be detected on X-Ray. These forms usually require a more challenging 
surgical reconstruction due to the  long gap between the upper and lower ends of the oesophagus.  
(Fig.1)  
168x231mm (300 x 300 DPI)  
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Figure 2 . Production of a tissue engineered oesophageal construct for neonatal oesophageal atresia(A). 
Surgical application for engineered segment in long-gap atresia with distal tracheo-oesophageal fistula (B)  
(Fig.2)  
196x140mm (96 x 96 DPI)  
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Condition  Description 
15-20% 
Anastomotic 
Leakage  
[88] 
Less than 30% comprise of major leaks that occur in early 
postoperative period (<48 hours), presenting with life-threatening 
tension pneumothorax.  
Treatment: emergency surgery required for major leaks.  Minor 
leaks will heal spontaneously.  
30-40% 
Anastomotic 
Stricture 
[89] 
Risk factors include anastomotic tension, leakage, and 
gastroesophageal reflux.  
Treatment: most strictures will respond to one or two dilatations.  
40% 
Gastro-
oesophageal 
reflux   
[90,91] 
More common following anastomosis under tension. Implicated in 
the pathogenesis of anastomotic stricture.  
Treatment: half of the cases do not respond to antireflux 
medication  and require surgery. 
75-100% 
Dysmotility 
[92] 
Uneven coordination of contractions due to abnormal innervation. 
Dysmotility is a major factor in long-term swallowing problems. 
Treatment: patients are advised to take fluids liberally with meals 
and avoid foodstuffs which exacerbate the problems.  
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  Model 
 Animal (n) 
 Defect site 
 Defect type 
Construct  
 Matrix origin 
 Decellularisati
on agents 
 Type of cells 
seeded 
Outcomes 
Survival  Vascular 
Growth 
Mucosa / 
epithelial 
coverage 
Muscle 
Organisation 
Contractility  Stricture  Fibrotic Tissue  
Badylak 
2000 [36]  
 
 
 Dog (n=15) 
 Cervical 
 A: 50% 
circular;        
B: 100% 
circular 
 Porcine ECM 
(SIS or UBM) 
 SIS: 0.1% 
Peracetic 
Acid; UBM: 
1.0N NaCl  
  
 A: Yes A&B: Yes 
(after 50 
days)  
A: Yes A: Yes A: No 
B: Yes 
 
Badylak 
2005 [93] 
 Dog (n=22) 
 Cervical 
 Circular 
endomucosal  
layer 
A: muscularis 
externa intact  
B: not intact 
 ECM sheet 
from UBM 
 0.1% Peracetic 
Acid 
  
A: 10/12 
for 26 – 
230 days 
B: 
Sacrificed 
at 3 wks 
due to 
stricture  
    A: No; 
B: Yes but 
lumen 
circumferenc
e <20% 
native 
A: Collagenous 
connective tissue 
present near 
sutures  
B: Yes  
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Freund 
2009  [62] 
 Dog (n=10) 
 Cervical 
 Circular 
endomucosal 
resection  
A: with scaffold 
placement  
B: without 
scaffold 
 ECM sheet 
from UBM 
 0.1% Peracetic 
Acid 
  
A: Yes;  
B: 3 
required 
early 
euthanasia, 
inability to 
tolerate oral 
intake.  
(I) Yes A: Yes; 
B: Yes 
incomplete 
  A&B: Yes A: No  
Isch 2001 
[94] 
 Dog (n=12) 
 Cervical 
 2x1cm patch 
 DHS 
(AlloDerm) 
  
  
100% 
survival 1-3 
months 
Yes Yes   No  
Bozuk 
2006 [95] 
 Human (n=1)  
 Thoracic 
 Post-operative 
dehiscence 
 DHS 
(AlloDerm)  
  
  
Patient 
survived 
the 
operation  
    No  
Urita 2007 
[48] 
 Rat (n=27) 
 Abdominal 
 3-4mm by 
5mm patch 
 Rat GAM 
 4% SDC, 
DNase I, 1M 
NaCl 
  
24 survived 
without 
complicatio
ns 
 Yes No  No  
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Lopes 2006 
[96]  
 Rat (n=85)  
 Cervical 
 A: Patch        
B: Circular  
 Porcine SIS 
  
  
Survival 
only in A 
 A: Yes A: Yes A: Yes A: No  
B: Yes  
 
Wei 2009 
[75] 
 Dog (n=12) 
 Cervical 
 5cm, 50% 
circular  
 Porcine SIS 
 Peracetic acid  
 Oral mucosal 
epithelial cells 
  Yes Yes    
Poghosyan 
2015 [38] 
 Minipig 
(n=18) 
 Cervical 
 Circular 
 Porcine SIS 
(Surgisis) 
  
 Skeletal 
Myoblasts 
A: SC + PS  
B: SC  
C: PS  
 
A: 6/6 
B: 1/6 
C: 1/6 
 Yes Yes    
Clough 
2011 [97] 
 Human (n=1) 
 Cervical 
 Perforation 
 Porcine SIS  
   
  
    Disrupted   
Doede 
2009 [98] 
 Piglet (n=14) 
 Cervical 
 Circular 
 Alloplastic 
SIS 
   
   
1/14 
survived 
over 4 
weeks 
    Yes  
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Gaujoux  
2010 [37] 
 
 Minipig 
(n=18)  
 Cervical 
 Circular  
 Fresh pig 
aortic allograft 
   
  
33% 
mortality 
first month. 
Stenting for 
6 mths 
crucial.  
No. 
Stopped by 
fibrosis 
Yes Yes. Fascicles 
and bundles 
observed 
No Yes Yes 
Kajitani 
2001 [46] 
 Pig (n=10) 
 Distal 
 Circular 
 Pig Aorta 
 DNase-I; 
Triton-X 
  
10/10 
survived 
over 6-16 
wks 
 Yes   Yes  
Marzaro 
2006 [47] 
 Pig (n=6) 
 Thoracic 
 Circular 
 Osophagus 
 4% SDC, 
DNase-I, 1M 
NaCl 
 Autologus 
Smooth 
Muscle Cell 
  Yes 
Capillary 
ingrowth 
observed 
Yes 
Fasciclues 
observed 
   
Sjoqvist 
2013 [48] 
 Rat (n=10)  
 Cervical 
 Circular 
 Oeesophagus 
 4% SDC, 
DNase-I, 
EDTA 
 Mesenchymal 
Stromal Cell 
10/10, 14 
days 
Yes Yes Yes    
 
Page 40 of 41
URL: http://mc.manuscriptcentral.com/eobt  Email: David.Grech@informa.com
Expert Opinion On Biological Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 
 
Aspect 
Characterised  
Technique Examples 
ECM architecture Staining Hematoxylin and Eosin, Masson's 
Trichrome, Alcian Blue, Van-
Gieson’s stain 
Immunohistochemistry  Laminin, Fibronectin, Collagen I & 
IV, Elastin 
Protein  Collagen, Glycosaminoglycan 
Mechanical Tests Pressure vs Distensibility, Burst 
Pressure, Force at break, % 
Elongation at break 
Imaging Transmission Electron Microscope,  
Scanning Electron Microscope 
Immunogenicity of 
matrix 
Immunohistochemistry Major histocompatibility complex I & 
II 
Alpha-Gal 
Assay DNA Assay  
In Vivo Subcutaneous Implantation 
Potential for 
Vascularisation  
Immunohistochemistry  Fibroblasts Growth Factor, Vascular 
Endothelial Growth Factor, Von 
Willebrand Factor 
In Vivo Chick Chorioallantoic Membrane 
assay, Subcutaneous Implantation 
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